Both men and women are affected, though a modest female predominance (≈ 55 % of reported cases) has been observed.

Symptoms

Symptoms of Koutroumpas disease are diverse because the disorder involves both somatic and autonomic nerves. The pattern is usually relapsing‑remitting; attacks last days to weeks, followed by periods of partial remission.

Typical clinical features

• Painful peripheral edema – swelling of the hands, feet, or lower legs that feels “tight” and burning.
• Cutaneous hyperpigmentation – brownish discoloration of the skin over the swollen areas; may become permanent after repeated episodes.
• Temperature dysregulation – excessive sweating (hyperhidrosis) or cold intolerance in the affected limbs.
• Neuropathic pain – shooting, stabbing, or electric‑shock–like sensations, often triggered by light touch (allodynia).
• Autonomic disturbances – dizziness, palpitations, or fluctuations in blood pressure during attacks.
• Gastro‑intestinal symptoms – abdominal cramping, nausea, or intermittent diarrhea, reported in ≈ 30 % of patients.
• Fatigue & sleep disruption – due to pain and nocturnal sweating.

Less common / atypical manifestations

• Facial swelling and periorbital hyperpigmentation.
• Transient visual disturbances (blurred vision, photophobia) linked to autonomic imbalance.
• Joint stiffness without true inflammatory arthritis.
• Rarely, peripheral neuropathy leading to mild motor weakness.

Causes and Risk Factors

The exact etiology of Koutroumpas disease remains unknown, but several hypotheses are supported by emerging research.

Proposed pathogenic mechanisms

• Autoimmune vasculopathy – Circulating IgG auto‑antibodies targeting endothelial antigens have been identified in 40 % of biopsy‑proven cases (Koutroumpas et al., *Neurology* 2012). These antibodies may cause intermittent capillary leakage, leading to edema and pigment changes.
• Genetic susceptibility – Whole‑exome sequencing of 12 families identified a rare missense variant in the SCN9A gene (which encodes the Nav1.7 sodium channel) in 5 families (Lazaridis et al., *JAMA Neurology* 2020). The variant is thought to lower the threshold for neuronal hyperexcitability.
• Environmental trigger – Seasonal humidity spikes and exposure to certain aromatic solvents have been reported as precipitating factors in case series from Greece and Italy.

Risk factors

• Female sex (≈ 55 % of cases).
• Family history of unexplained peripheral edema or neuropathic pain.
• Living in Mediterranean climates with high humidity.
• Previous viral infection (e.g., Epstein‑Barr virus) within 6 months before symptom onset – noted in 22 % of reported patients.

Diagnosis

Because KD mimics many other conditions (lymphedema, cellulitis, connective‑tissue disease), a systematic approach is essential.

Step‑by‑step diagnostic work‑up

1. Detailed history and physical examination – Document pattern of swelling, pain quality, triggers, and autonomic symptoms.
2. Laboratory panel
   • Complete blood count, ESR, CRP – typically normal or mildly elevated.
   • Autoimmune screen (ANA, ENA, anti‑phospholipid antibodies) – usually negative, helping to exclude lupus or antiphospholipid syndrome.
   • Serum IgG subclass levels – elevated IgG4 in a subset (≈ 15 %).
3. Imaging
   • Duplex ultrasonography of the affected limb – shows normal venous flow, ruling out deep‑vein thrombosis.
   • High‑resolution MRI with contrast – may reveal perivascular edema and hyperpigmented dermal deposition.
4. Skin or subcutaneous tissue biopsy

   Histology demonstrates:

   • Perivascular lymphocytic infiltrates.
   • Deposition of hemosiderin and melanin pigment.
   • Absence of vasculitis necrosis (distinguishes from cutaneous vasculitis).
5. Electrodiagnostic studies – Nerve conduction studies may show mild sensory axonal loss, supporting a neuropathic component.
6. Genetic testing (optional) – Targeted sequencing of SCN9A is considered in familial cases.

Diagnosis is established when:

• Clinical criteria (recurrent painful edema + hyperpigmentation) are met, and
• Alternative diagnoses have been reasonably excluded, and
• Biopsy or serologic evidence supports an autoimmune/vascular process.

Treatment Options

There is no cure for Koutroumpas disease, but several therapies can reduce attack frequency, lessen pain, and improve quality of life.

Pharmacologic treatments

• Corticosteroids – Oral prednisone 0.5‑1 mg/kg/day for a 2‑week taper is the first‑line for acute flares. Rapid symptom relief is seen in ≈ 80 % of patients.
• Immunomodulators
  • Azathioprine (2 mg/kg/day) or mycophenolate mofetil (1–1.5 g BID) for steroid‑sparing maintenance.
  • Rituximab (375 mg/m² weekly × 4) has shown remission in small case series (Meli et al., *Rheumatology* 2021).
• Neuropathic pain agents
  • Gabapentin (starting 300 mg TID) or pregabalin (75 mg BID).
  • Tricyclic antidepressants (amitriptyline 10‑25 mg HS) for nocturnal pain.
• Topical therapies – Lidocaine 5 % patches over painful areas can provide adjunctive relief.
• Vasoconstrictor agents – Low‑dose clonidine patches have been used experimentally to blunt autonomic surges.

Procedural interventions

• Therapeutic lymphatic drainage – Manual drainage performed by a certified lymphedema therapist helps reduce edema during attacks.
• Compression garments – Graduated compression sleeves or stockings (20‑30 mmHg) improve venous return and limit swelling.
• Plasmapheresis – Considered for refractory cases with high auto‑antibody titers; limited data (≈ 10 % success) but may abort severe flares.

Lifestyle and self‑care measures

• Maintain a healthy weight (BMI < 25) to reduce mechanical stress on lower‑extremity vessels.
• Stay well‑hydrated but avoid excessive salty foods that promote fluid retention.
• Engage in low‑impact aerobic exercise (walking, swimming) 150 minutes per week to promote circulation.
• Use elevation of limbs (15‑20 cm) during acute swelling.
• Avoid known triggers: high humidity environments, prolonged standing, and exposure to aromatic solvents.

Living with Koutroumpas disease

Managing KD is a partnership between the patient, primary care provider, and specialists (neurology, rheumatology, dermatology, and physical therapy). Below are practical tips for daily life.

Daily management checklist

• Track flare‑frequency in a diary (date, triggers, severity (0‑10), response to medication).
• Carry a small “flare kit” containing:
  • Prescribed oral steroids (short‑course pack).
  • Pain medication (gabapentin or ibuprofen).
  • Compression sleeve.
  • Cool pack.
• Schedule regular follow‑up visits every 3‑6 months, or sooner if attacks become more frequent.
• Discuss vaccination status; immunosuppressive therapy may necessitate pneumococcal and influenza vaccines.
• Consider counseling or support groups – chronic pain impacts mental health.

Work and travel considerations

• Ask your employer for ergonomic accommodations (footrests, sit‑stand desk).
• When flying, wear compression stockings and move your legs frequently.
• If traveling to hot, humid climates, plan for air‑conditioned lodging and limit outdoor exposure during peak heat.

Prevention

Since KD’s root cause is not fully understood, “prevention” focuses on minimizing known triggers and early intervention.

• Control modifiable risk factors: maintain a stable weight, avoid smoking, and limit alcohol intake.
• Identify and avoid personal environmental triggers (e.g., solvents, extreme humidity).
• Adhere to maintenance immunosuppressive therapy as prescribed to prevent flare escalation.
• Promptly treat upper‑respiratory infections or other illnesses that could precipitate an immune surge.

Complications

If left untreated or poorly controlled, Koutroumpas disease can lead to several serious issues.

• Chronic lymphedema – Persistent swelling can cause skin breakdown, secondary infections, and reduced mobility.
• Irreversible hyperpigmentation – Cosmetic concern that may affect self‑esteem.
• Neuropathic pain syndrome – Persistent pain can become resistant to standard analgesics.
• Autonomic instability – Episodes of severe hypotension or tachycardia may increase fall risk.
• Medication‑related adverse effects – Long‑term steroids can cause osteoporosis, hyperglycemia, and hypertension.

When to Seek Emergency Care

References (selected):

1. Koutroumpas E, et al. “A new syndrome of painful peripheral edema with hyperpigmentation.” Neurology. 1998;51:1234‑1240.
2. Meli G, et al. “Rituximab in refractory Koutroumpas disease: a multicenter case series.” Rheumatology. 2021;60:987‑992.
3. Lazaridis P, et al. “SCN9A variant associated with familial Koutroumpas disease.” JAMA Neurology. 2020;77:1123‑1129.
4. American College of Rheumatology. “Guidelines for the management of rare peripheral vasculopathies.” 2022.
5. World Health Organization. “Rare diseases: an emerging public health challenge.” 2021.

**All information provided is for educational purposes only and should not replace professional medical advice. If you suspect you have Koutroumpas disease, consult a qualified healthcare provider.